Literature DB >> 22745248

Modifications in the papillary thyroid cancer gene profile over the last 15 years.

Cristina Romei1, Laura Fugazzola, Efisio Puxeddu, Francesco Frasca, David Viola, Marina Muzza, Sonia Moretti, Maria Luisa Nicolosi, Carlotta Giani, Valentina Cirello, Nicola Avenia, Stefania Rossi, Paolo Vitti, Aldo Pinchera, Rossella Elisei.   

Abstract

BACKGROUND: Evidence for an increased prevalence of BRAF(V600E) mutations has been documented in recent decades. The aim of this study was to evaluate the prevalence of both RET/PTC rearrangements and BRAF(V600E) mutations in an Italian cohort of papillary thyroid carcinoma (PTC) patients followed at the Endocrine Units of Pisa, Milano, and Perugia from 1996-2010. PATIENTS AND METHODS: In total, 401 PTC patients were examined and grouped according to the time of surgery: group 1, 1996-2000; group 2, 2001-2005; and group 3, 2006-2010. Patients were analyzed for clinical, pathological, and molecular features. In parallel, the molecular characteristics of 459 PTC from Sicily were studied.
RESULTS: The genetic profiles of the three groups were significantly different (P < 0.0001). In particular, the frequency of RET/PTC rearrangements decreased from 1996-2010, occurring in 33 of 100 (33%) of the patients in group 1, 26 of 148 (17%) in group 2, and 15 of 153 (9.8%) in group 3. The incidence of BRAF(V600E) mutations increased over the same period, from 28% in group 1 (28 of 100) to 48.9% in group 2 (73 of 148) and 58.1% in group 3 (89 of 153). A consistent increase in BRAF(V600E) prevalence was observed in the Sicilian group (P < 0.0001). Moreover, a statistically significant increase in the mean age at diagnosis and decrease in tumor size over the study period was observed.
CONCLUSION: The genetic profile of PTC changed over the last 15 yr, with a significant decrease in the prevalence of RET/PTC rearrangements and an increase in BRAF(V600E) mutations. In addition, the mean age at diagnosis increased and tumor size decreased over the study period.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22745248     DOI: 10.1210/jc.2012-1269

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  30 in total

1.  Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with "suspicious for malignant" cytology alone even when the nodules do not show suspicious US features.

Authors:  Jae Young Seo; Eun-Kyung Kim; Jin Young Kwak
Journal:  Endocrine       Date:  2014-01-23       Impact factor: 3.633

Review 2.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

3.  Molecular profiles of papillary thyroid tumors have been changing in the last decades: how could we explain it?

Authors:  Rossella Elisei
Journal:  J Clin Endocrinol Metab       Date:  2014-02       Impact factor: 5.958

4.  Thyroid nodules ≥ 4 cm: can ultrasound and cytology reliably exclude cancer? Reply.

Authors:  Linwah Yip
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

Review 5.  The changing incidence of thyroid cancer.

Authors:  Cari M Kitahara; Julie A Sosa
Journal:  Nat Rev Endocrinol       Date:  2016-07-15       Impact factor: 43.330

6.  Pediatric Thyroid Cancer Incidence and Mortality Trends in the United States, 1973-2013.

Authors:  Z Jason Qian; Michael C Jin; Kara D Meister; Uchechukwu C Megwalu
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2019-07-01       Impact factor: 6.223

7.  Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.

Authors:  Hyeyeun Lim; Susan S Devesa; Julie A Sosa; David Check; Cari M Kitahara
Journal:  JAMA       Date:  2017-04-04       Impact factor: 56.272

8.  Germline and somatic mutations of the APC gene in papillary thyroid carcinoma associated with familial adenomatous polyposis: Analysis of three cases and a review of the literature.

Authors:  Kensuke Kumamoto; Hideyuki Ishida; Tomonori Ohsawa; Keiichiro Ishibashi; Mineko Ushiama; Teruhiko Yoshida; Takeo Iwama
Journal:  Oncol Lett       Date:  2015-08-06       Impact factor: 2.967

Review 9.  A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.

Authors:  Cristina Romei; Raffaele Ciampi; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2016-02-12       Impact factor: 43.330

10.  The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.

Authors:  Daniele Barbaro; Roberto Mario Incensati; Gabriele Materazzi; Giuseppe Boni; Mariano Grosso; Erica Panicucci; Paola Lapi; Cristina Pasquini; Paolo Miccoli
Journal:  Endocrine       Date:  2013-08-08       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.